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ystrophin-deﬁcient muscles experience large reduc-
tions in expression of nitric oxide synthase (NOS),
which suggests that NO deﬁciency may inﬂuence
the dystrophic pathology. Because NO can function as an
antiinﬂammatory and cytoprotective molecule, we propose
that the loss of NOS from dystrophic muscle exacerbates
 
muscle inﬂammation and ﬁber damage by inﬂammatory
cells. Analysis of transgenic mdx mice that were null
mutants for dystrophin, but expressed normal levels of NO
in muscle, showed that the normalization of NO production
caused large reductions in macrophage concentrations in
 
the mdx muscle. Expression of the NOS transgene in
mdx muscle also prevented the majority of muscle mem-
brane injury that is detectable in vivo, and resulted in
D
 
large decreases in serum creatine kinase concentrations.
Furthermore, our data show that mdx muscle macrophages
are cytolytic at concentrations that occur in dystrophic,
NOS-deﬁcient muscle, but are not cytolytic at concentra-
tions that occur in dystrophic mice that express the NOS
transgene in muscle. Finally, our data show that antibody
depletions of macrophages from mdx mice cause signiﬁ-
cant reductions in muscle membrane injury. Together,
 
these ﬁndings indicate that macrophages promote injury
of dystrophin-deﬁcient muscle, and the loss of normal
levels of NO production by dystrophic muscle exacer-
bates inﬂammation and membrane injury in muscular dys-
trophy.
 
Introduction
 
Duchenne muscular dystrophy (DMD)* is one of the most
prevalent and lethal inherited diseases of childhood. The defi-
cient gene product, dystrophin (Hoffman et al., 1987), is a
membrane-associated protein that provides a link in a chain
of proteins between the actin cytoskeleton and the extracellu-
lar matrix (Ibraghimov-Beskrovnaya et al., 1992). The partic-
ipation of dystrophin in this chain of proteins suggests that
dystrophin serves a structural role in muscle cells. In addition,
dystrophin deficiency in the mdx mouse model of DMD is
associated with an increase in cell membrane lesions that can
be detected by the presence of elevated creatine kinase (CK)
levels in the serum, or by the presence of extracellular marker
dyes within the muscle fibers (McArdle et al., 1994; Matsuda
et al., 1995). These observations have provided the key evi-
dence for the “mechanical defect hypothesis,” in which the
loss of dystrophin from muscle is interpreted as causing mus-
cle cell death by producing a cell membrane that more fre-
quently experiences lethal, mechanical damage.
Part of the complexity in understanding the impact of dys-
trophin deficiency on muscle cell viability results from the sec-
ondary loss of the entire complex of proteins that interact
with dystrophin at the muscle cell surface (Ervasti et al.,
1990). Although the functions of most of these proteins re-
main obscure, neuronal nitric oxide synthase
 
 
 
(nNOS) is a
prominent member of the complex (Brenman et al., 1995)
that has well-characterized functions in several tissues. In the
absence of dystrophin, the concentration of nNOS at the cell
membrane (Brenman et al., 1995) and in the cytoplasm
(Chang et al., 1996) decreases tremendously, and the concen-
tration of nNOS mRNA is also greatly diminished (Chang et
al., 1996). Thus, it is feasible that the secondary loss of nNOS
from muscle contributes significantly to the dystrophic pa-
thology. Previous work has shown that mdx mice that are null
mutants for nNOS show no detectable difference in muscle
pathology compared with mdx mice which contain low levels
of cytosolic nNOS (Chao et al., 1998; Crosbie et al., 1998).
In addition, nNOS null mice that express dystrophin do not
show muscular dystrophy (Chao et al., 1998; Crosbie et al.,
1998), although that observation is not sufficient to conclude
 
Address correspondence to James G. Tidball, Department of Physiologi-
cal Science, University of California at Los Angeles, 5833 Life Science
Building, Los Angeles, CA 90095. Tel.: (310) 206-3395. Fax: (310) 206-
8389. E-mail: jtidball@physci.ucla.edu
 
*Abbreviations used in this paper: CK, creatine kinase; DMD, Duchenne
muscular dystrophy; MHC-II, major histocompatibility complex class II;
nNOS, neuronal NOS; NO, nitric oxide; NOS, NO synthase; Tg, transgenic.
Key words: muscle; muscular dystrophy; nitric oxide synthase; macro-
phages; inﬂammation 
124 The Journal of Cell Biology 
 
|
 
 
 
Volume 155, Number 1, 2001
 
that nNOS deficiency is unimportant in dystrophinopathy.
Null mutants for nNOS that express dystrophin and other
members of the dystrophin complex would not have the pri-
mary defect of dystrophin deficiency that could then be exac-
erbated by the secondary loss of nNOS.
We propose that nNOS deficiency in dystrophic muscle
could significantly promote muscle pathology if NO were to
serve an antiinflammatory role in injured muscle. Dystro-
phinopathies are characterized by high concentrations of
myeloid cells within the muscle (Arahata and Engel, 1984;
McDouall et al., 1990; Gorospe et al., 1994; Cai et al.,
2000). Although the possibility that these myeloid cells pro-
mote dystrophy has not been examined previously, they are
known to be cytotoxic in other pathological conditions (Jan-
sen et al., 1994; Jun et al., 1999). Furthermore, NO has
been shown to inhibit the diapedesis, activation, and longev-
ity of select myeloid cell populations (Clancy et al., 1992;
Albina et al., 1993; Liu et al., 1998), so it is feasible that the
loss of NO from dystrophic muscle would result in increased
muscle inflammation. Finally, NO can scavenge cytolytic
molecules that are generated by myeloid cells, so that a re-
duction in NO production could yield muscle that is more
susceptible to lysis during inflammation.
 
Results
 
Normalization of NO production in mdx mice reduces 
muscle pathology in mdx mice
 
Western, Northern, and gene array analyses of NOS trans-
genic (Tg) muscles showed that there is an 
 
 
 
250-fold in-
crease in NOS mRNA and a 50-fold increase in NOS pro-
tein in muscles (Fig. 1, A and B). However, there is only an
 
 
 
0.2-fold increase in NO production by soleus muscle from
NOS Tg mice compared with controls (Fig. 1 C). The rela-
tively small increase in NO production relative to elevation
of NOS protein in the NOS Tg muscles may reflect the in-
creased expression of endogenous inhibitors of NOS. For ex-
ample, gene array analysis and Western blots show a 10-fold
increase in protein inhibitor of NOS in the NOS Tg mus-
cles (unpublished data).
NOS Tg mice were crossed with mdx mice to generate
NOS Tg/mdx mice. Measurements of NO production by
age-matched solei from C57 controls, mdx, or NOS Tg/
mdx muscles showed that the decrease in NOS in mdx mus-
cle resulted in a reduction of NO production by 
 
 
 
80%
(Fig. 1 C). However, the NOS Tg returned the levels of
muscle NO production to values that did not differ signifi-
cantly from controls (Fig. 1 C). Normalization of NO pro-
duction in NOS Tg/mdx muscles resulted in amelioration of
all of the key indices of histopathology in dystrophin-defi-
cient muscle (Fig. 2). For example, 4 wk mdx mouse muscle
contains high concentrations of macrophages, central-nucle-
ated muscle fibers, and high variability in muscle fiber diam-
eter (Figs. 2–4). However, normalized NO production in
dystrophin-deficient mice yields a 60% decrease in central-
nucleated fibers in 4-wk-old mice (Fig. 3). In addition,
4-wk-old NOS Tg/mdx mice showed a 50% reduction in
the concentration of macrophages and cells expressing major
histocompatibility complex class II (MHC-II) (Fig. 3). NOS
Tg/mdx mice also show an 
 
 
 
50% reduction in the patho-
logical variability in fiber size seen in mdx muscle (Fig. 4 A).
Although it is feasible that the presence of the transgene
Figure 1. Northern analysis of NOS Tg muscles. (A) Lanes 1–3 
contained total RNA isolated from muscles that did not express the 
NOS transgene. Lane 4 was loaded with an equal mass of total RNA 
that was obtained from muscles of a NOS Tg mouse. The blot was 
probed with cDNA for full-length nNOS. The mass of the wild-type 
nNOS is greater than the transgenic nNOS, because the wild-type 
encodes an additional 34 amino acid nNOS  peptide. (B) Western 
analysis of NOS Tg muscles. Muscle samples from littermates of 
NOS Tg mice that did not express the NOS transgene (three left 
lanes) and from NOS Tg mice (three right lanes). Densitometric 
analysis of the relative quantities of nNOS shows an  50-fold 
increase in nNOS in the NOS/Tg muscles. (C) NO release from 
control, NOS Tg, mdx, and NOS Tg/mdx. NO release from solei 
was measured for muscles obtained from C57 (white bar; n   10), 
NOS Tg (black bar; n   10), mdx (stippled bar; n   8), and NOS Tg/
mdx mice (striped; n   8). Asterisk, differs from C57 at P   0.05. 
Error bars indicate standard errors of the means in all figures.
Figure 2. Sections of 4-wk-old soleus muscles stained by hematoxylin. 
(A) C57 muscle showing fibers of uniform diameter, no central 
nucleation, and no clusters of inflammatory cells between adjacent 
fibers. (B) Mdx muscle showing a typical focus of muscle pathology 
characterized by fiber populations of variable diameters and central 
nucleation. Dark staining nuclei of inflammatory cells appear 
between adjacent fibers. (C) NOS Tg/mdx muscle showing typical 
histology, where fiber diameter is more uniform than age-matched 
mdx muscle, and there is little inflammation or central nucleation. 
(D) NOS Tg/mdx muscle showing an example of the relatively small 
lesions that appear in NOS Tg/mdx muscle (between arrows) where 
there are small clusters of small-diameter, central-nucleated fibers. 
All micrographs are at the same magnification. Bar, 250  m. 
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could diminish pathology through an effect that was inde-
pendent of normalized NO production, the finding that
NOS inhibition reversed the ameliorative effects of the
transgene argues strongly against that possibility. The reduc-
tion in macrophage concentration, MHC-II
 
 
 
 cell concen-
tration, central-nucleated fibers, and fiber injury (Figs. 3 and
4) that were observed in NOS Tg/mdx muscles did not oc-
cur if the NOS Tg/mdx mice received L-NAME treatments.
We further tested whether the reduction of these indices
of dystrophic pathology by the NOS transgene resulted
from a delay in the onset of the pathology, rather than an
ameliorization of the pathology, by evaluating soleus mus-
cles from 3-mo-old NOS Tg/mdx mice and mdx mice that
did not express the transgene. NOS Tg/mdx mice showed
significantly less central nucleation at 3 mo of age than was
observed in littermates that did not express the transgene
(Fig. 3 C). This indicates that the cumulative muscle injury
and regeneration experienced by the NOS Tg/mdx mice re-
mains less than that which occurs in mdx mice, and also
supports the interpretation that the transgene reduces the
pathology rather than delays its onset.
Figure 3. Expression of the NOS transgene reduces mdx muscle 
inflammation and regeneration. The concentrations of macro-
phages (A), MHC class II  cells (B), and regenerative fibers (C) were 
measured in quadriceps from 4-wk-old C57 (black bars; n   10), 
4-wk-old mdx (striped bars; n   10), 4-wk-old NOS Tg/mdx (gray 
bars; n   10), 4-wk-old, L-NAME–treated NOS Tg/mdx muscles 
(white bars; n   6), 3-mo-old mdx (striped bars; n   13), and 
3-mo-old, NOS Tg/mdx (grey bars; n   5). Asterisk, differs from C57 
(P   0.05); pound sign, differs from age-matched mdx (P   0.05).
Figure 4. Expression of the NOS transgene reduces muscle fiber 
variability in size (A) and muscle fiber injury (B). Histogram shows 
variability in fiber diameter of 4-wk-old C57 (black bars; n   10), 
4-wk-old mdx (striped bars; n   10), 4-wk-old NOS Tg/mdx (gray 
bars; n   10), 4-wk-old, L-NAME–treated NOS Tg/mdx muscles 
(white bars; n   6), 3-mo-old mdx (striped bars; n   13), and 3-mo-old 
NOS Tg/mdx (grey bars; n   5). (A) The data represent the mean of 
the standard deviation of fibers. (B) The data are the percentage of 
total fibers that contain procion red. Asterisk, differs from C57 
(P   0.05); pound sign, differs from age-matched mdx (P   0.05). 
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Comparison of the concentrations of macrophages in
3-mo-old NOS Tg/mdx and in mdx mice showed that mac-
rophages decline in concentration in both the transgenic and
control mice between 1 and 3 mo of age (Fig. 3 A). A nearly
identical change was seen in the concentrations of MHC-II–
expressing cells (Fig. 3 B). These findings also indicate that
expression of the transgene reduces dystrophinopathy, rather
than delaying its onset.
 
Normalization of NO production in mdx mice reduces 
muscle membrane damage
 
NOS Tg/mdx mice showed a 70% decrease in the number
of fibers possessing membrane lesions when compared with
mdx mice (Figs. 4 B and 5). The proportion of injured fibers
in NOS Tg/mdx mice remained significantly less than mdx
mice at 3 mo of age, and fiber injury in NOS Tg/mdx mus-
cles did not increase from 1 to 3 mo of age. Muscle mem-
brane injury was also assessed by measuring serum CK con-
centration, which showed a similar 70% reduction in serum
CK concentration in 4-wk-old NOS Tg/mdx compared
with mdx (Fig. 6). However, both the NOS Tg/mdx and the
mdx mice showed a trend for increased serum CK concen-
tration at 3 mo of age and an increase in interanimal vari-
ability in serum CK concentration. The difference in CK
concentration between the transgenic and control mdx was
no longer significant at
 
 P 
 
 
 
 0.05.
 
Normalization of NO production in mdx mice does not 
affect muscle vascularity
 
Vascularity of 4-wk-old NOS Tg/mdx mice and mdx mice
that did not express the transgene was assessed by measuring
capillary density and vascular volume fraction in soleus mus-
cle. Both indices showed that there is no difference in the vas-
cularity of mdx muscle that is caused by normalized NO pro-
duction. Mdx mouse soleus muscles contained 6.96% of the
total muscle volume in vascular luminal space (
 
n
 
 
 
 
 
 10; SEM 
 
 
 
0.56), and 6.95% of NOS Tg/mdx soleus muscle volume
consisted of vascular lumen (
 
n
 
 
 
 
 
 10; SEM 
 
 
 
 0.36). The cap-
illary density in mdx soleus muscles was 110 capillaries/mm
 
2
 
(
 
n
 
 
 
 
 
 10; SEM 
 
 
 
 10.8), and the capillary density in NOS Tg/
mdx solei was 116 capillaries/mm
 
2
 
 (
 
n
 
 
 
 
 
 10; SEM 
 
 
 
 10.4).
 
Mdx muscle macrophages at pathophysiological 
concentrations lyse muscle cells
 
The observations reported above show that normalization of
NO production in mdx muscle reduced muscle membrane
lesions and inflammation. These reductions in inflammation
and membrane damage did not occur in NOS Tg/mdx mice
Figure 5. Expression of the NOS trans-
gene reduces muscle membrane 
lesions. Solei of C57 mice showed 
procion red almost exclusively located 
extracellularly (A), indicating infrequent 
occurrence of membrane lesions. Mdx 
muscles (B) showed that  8% of the 
fibers were injured and contained 
procion red. NOS Tg/mdx muscles 
(C and D) showed a frequency of 
procion red–containing injured fibers 
that was reduced to levels nearing C57 
controls. Bar, 100  m.
Figure 6. Expression of the NOS transgene reduces the concen-
tration of serum CK in mdx mice. 4-wk-old C57 (black bars; n   5), 
4-wk-old mdx (striped bars; n   12), 4-wk-old NOS Tg/mdx (gray 
bars; n   5), 4-wk-old, L-NAME–treated NOS Tg/mdx muscles 
(white bars; n   6), 3-mo-old, mdx (striped bars; n   13), and 
3-mo-old NOS Tg/mdx (grey bars; n   5). Asterisk, differs from C57 
(P   0.05); pound sign, differs from age-matched mdx (P   0.05). 
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that were treated with the NOS inhibitor, L-NAME. This
may indicate that NO functions as an antiinflammatory
molecule, and that its normalization reduced macrophage-
mediated damage to mdx fibers. Measurements show that
macrophage concentrations can exceed 5 
 
 
 
 10
 
4
 
 macro-
phages/mm
 
3
 
 muscle in 4 wk mdx soleus muscles (Fig. 7 A).
We tested whether this concentration was sufficient to cause
muscle membrane lysis in vitro by cytotoxicity assays using
macrophages that were isolated from 4 wk mdx muscle.
Greater than 40% of target myotubes were lysed within 16 h
of coincubation with 5 
 
  
 
10
 
4
 
 mdx muscle macrophages/
mm
 
3
 
, which indicates that these macrophages are potently
cytolytic at this concentration (Fig. 7 B). However, 10
 
4
 
 mac-
rophages/mm
 
3
 
, which is the concentration observed in
4-wk-old NOS Tg/mdx muscles and in prenecrotic 2-wk-
old mdx muscles, showed little cytotoxicity (Fig. 7 B).
We further tested whether mdx muscle macrophages lyse
muscle membranes in vivo by depleting macrophages and
assessing the occurrence of membrane lesions by entry of
procion red into soleus muscle fibers. Muscles analyzed from
macrophage-depleted mdx mice showed a 
 
 
 
75% reduction
in injured fiber concentration compared with nondepleted
mdx mice (Figs. 7 C and 8).
 
Macrophage depletions from mdx muscles reduce the 
concentration of regenerative muscle fibers
 
We tested whether the reduction in muscle membrane in-
jury in macrophage-depleted mdx mice resulted from in-
creased muscle repair and regeneration by measuring the
proportion of fibers in depleted and control mdx soleus
muscles that contained central nuclei. PBS-injected mdx
mice contained 31.2% central-nucleated fibers in soleus
muscle (SE 
 
 
 
 5.0;
 
 n 
 
 
 
 6) and macrophage-depleted mice
contained 9.9% (SE 
 
 
 
 2.7;
 
 n 
 
 
 
 8; differs from control at
 
P 
 
 
 
 0.002). This indicates that the cumulative muscle in-
jury and regeneration experienced by macrophage-depleted
mdx mice is less than control mdx mice, and that the propor-
tion of central-nucleated fibers observed in 4-wk-old, macro-
phage-depleted mice is similar to the proportion in NOS Tg/
mdx mice. This eliminates the possibility that either the nor-
malization of NO production or macrophage depletion de-
creases mdx pathology by promoting regeneration.
 
Discussion
 
Mechanical damage to the cell membrane of dystrophin-
deficient muscle may disrupt normal muscle homeostasis and
lead to muscle cell pathology (Petrof et al., 1993). Mem-
brane damage can also permit the unregulated transit of ex-
tracellular calcium into the cytoplasm that can increase acti-
vation of calcium-dependent proteases, which may promote
muscle mass loss and muscle destruction (Spencer et al.,
1995). The central importance of membrane lesions in the
progression of dystrophinopathy has provided the founda-
tion for studies directed toward increasing the expression of
other proteins that may be able to recover membrane stabil-
ity and prevent muscle damage in the absence of dystrophin.
For example, elevating the expression of the dystrophin ho-
mologue utrophin (Tinsley et al., 1996) or dystrophin com-
plex analogue 
 
 
 
7-integrin (Burkin et al., 2001) have both
Figure 7. Macrophage concentration in mdx solei. (A) C57 (solid 
bars). Mdx (striped bars). Asterisk, differs from age-matched controls 
(P   0.05). Pound sign, differs from all other data sets (P   0.05). 
n   14 for each data set. (B) Mdx muscle macrophages kill muscle 
cells in vitro. Values show the percentage lysis of C2C12 myotubes 
by macrophages isolated from 4-wk-old mdx muscles. Solid bars, 
nonactivated macrophages. Striped bars, PMA-activated macro-
phages. Asterisk, differs from C57 at P   0.05. (C) Macrophage 
depletions reduce muscle membrane lesions. Data are the percent-
age of total muscle fibers in cross-sections of soleus muscle that 
contain intracellular procion red. Approximately 9% of the total 
fibers were injured and contained procion red in solei of mdx mice 
receiving intraperitoneal injections of PBS (black bar). Approxi-
mately 2% of the fibers of the fibers of mdx mice receiving intraperi-
toneal injections of anti-F4/80 showed intracellular procion red 
(striped bar). Asterisk, differs from PBS at P   0.05.128 The Journal of Cell Biology | Volume 155, Number 1, 2001
been effective at preventing muscle membrane injury in dys-
trophin-deficient mice and reducing pathology.
Our findings show that nonmechanical factors contribute
importantly to membrane damage in dystrophinopathy.
Normalization of NO production reduced the occurrence of
many of the key indices of pathology that are characteristic
of dystrophinopathy, such as central nucleation, inflamma-
tion, and fiber membrane damage. These observations are
consistent with the view that muscle membrane lesions con-
tribute to dystrophic muscle pathology. However, these
findings also indicate that a large proportion of the lesions
are the consequence of nNOS deficiency, rather than the di-
rect result of mechanical damage.
Findings presented here support the conclusion that the
protective effect of normalized NO production in dystro-
phin-deficient muscle is attributable to antiinflammatory ac-
tions of NO. Most importantly, the large reduction of
inflammation of NOS Tg/mdx muscle supports this inter-
pretation. Previous investigations conducted in vitro have
shown potential mechanisms through which NO could in-
hibit inflammation. For example, NO can reduce diapedesis
of myeloid cells by inhibition of P-selectin and ICAM ex-
pression (Liu et al., 1998), and NO can induce leukocyte
apoptosis (Albina et al., 1993). Furthermore, NO can inhibit
target cell cytolysis by myeloid cells by inhibiting the expres-
sion or activity of enzymes that generate cytolytic free radi-
cals (Clancy et al., 1992; Abu-Soud and Hazen, 2000), and
by scavenging free radicals that are generated by inflamma-
tory cells (Miles et al., 1996). These antiinflammatory and
free radical–scavenging functions of NO may be especially
important in regulating the mdx pathology, because dystro-
phin-deficient muscle cells are more sensitive than control
muscle to cytolysis that is induced by free radicals (Rando et
al., 1998). The present findings, which show that macro-
phage depletion yields protection against muscle membrane
lesions that is similar to that produced by normalization of
NO production, supports the interpretation that normalized
NO production protects dystrophic muscle from macro-
phage-mediated damage.
Inflammation in muscular dystrophy has been previously
considered to be an inconsequential response to muscle in-
jury, rather than a contributor to the pathological progres-
sion. However, the long-recognized benefits of some immu-
nosuppressants in slowing the progress of dystrophinopathy
have suggested that immune cells may contribute to the pa-
thology (Drachman et al., 1974). Our findings, which show
that macrophages that are isolated from mdx muscle are ca-
pable of lysing muscle cells in vitro, support the possibility
that they may be directly cytotoxic in dystrophic muscle.
The decrease in mdx muscle membrane damage after anti-
body depletions of macrophages is also consistent with a cy-
totoxic role of macrophages in mdx dystrophy. However,
macrophages may also mediate cytotoxicity through less di-
rect routes in mdx dystrophy if they were to activate other
cytotoxic cells. Previous work has shown that depletion of
CD8  T cells (Spencer et al., 1997) or CD4  T cells
(Spencer et al., 2001) from mdx mice before the peak of pa-
thology causes a reduction in histologically discernible pa-
thology in dystrophic muscles. It is possible that mdx muscle
macrophages activate autoaggressive T cells in mdx muscle,
and thereby promote cytotoxicity indirectly.
Previous investigations have indicated that NOS deficiency
in dystrophic muscle could exacerbate muscle pathology by
disrupting normal regulation of blood flow, or by influencing
angiogenesis. For example, mdx mice and DMD boys have an
impaired ability to inhibit  -adrenergic–stimulated vasocon-
striction (Thomas et al., 1998; Sander et al., 2000). However,
both peripheral blood flow and vascular conductance in rest-
ing and contracting muscles were shown to be unaffected by
the decreased concentration of nNOS in mdx muscles in vivo
(Thomas et al., 1998). Those findings indicate that muscle
nNOS would be important in modulating muscle blood flow,
primarily in animals in which vasoconstriction was caused by
increased sympathetic outflow. Whether nNOS-derived NO
can induce vasodilation in vivo through mechanisms that do
not involve inhibition of  -adrenergic–stimulated vasocon-
striction has not been demonstrated. However, excised muscle
subjected to electrical stimulation does experience vasodila-
tion via the cGMP cascade (Lau et al., 2000; Grange et al.,
2001). Although we were aware of no environmental stimuli
that would have caused increased sympathetic outflow in the
animals used in the present investigation, it is not possible to
completely exclude that possibility.
Other reports have also shown that NO can either pro-
mote (Ziche et al., 1994; Montrucchio et al., 1997) or in-
hibit (Powell et al., 2000) angiogenesis, which could provide
yet another mechanism through which normalization of
NO production by dystrophic muscle could affect tissue pa-
thology. However, our results show that the presence of the
NOS transgene in mdx muscle did not affect capillary den-
sity or the volume fraction of the muscle that consisted of
vascular structures. Thus, the effects of normalized NO pro-
duction on dystrophinopathy are not attributable to an NO
influence on angiogenesis.
Figure 8. Macrophage depletions 
reduce mdx muscle fiber injury. Soleus 
muscles from 4-wk-old mdx mice 
showed a frequent occurrence of fibers 
with intracellular procion red, indicating 
the presence of membrane lesions (A). 
Depletion of circulating macrophages by 
anti-F4/80 injections decreased the 
occurrence of membrane lesions (B). 
Bar, 100  m.Expression of a NOS transgene reduces dystrophinopathy | Wehling et al. 129
Several previous observations have suggested the possibil-
ity that reductions in muscle NO production could affect
muscle differentiation and regeneration (Lee et al., 1994;
Anderson, 2000) and thereby influence the pathology of
dystrophin-deficient muscle. For example, inhibition of
muscle NOS activity significantly reduces the capacity
of mononucleated muscle cells to fuse and differentiate into
multinucleated myotubes in vitro (Lee et al., 1994). Thus, it
is feasible that normalization of NO production in dystro-
phic muscle could reduce muscle pathology by promoting
regeneration, rather than by decreasing damage. However,
we have found that the NOS transgene greatly reduces the
proportion of mdx muscle fibers that contain central nuclei,
which are persistent indicators of fibers that have been dam-
aged and experienced regeneration or repair. The reduction
in regenerative fibers indicates that normalized NO produc-
tion ameliorates the dystrophic pathology by reducing the
initial damage to dystrophic muscle, rather than increasing
regeneration.
We propose a model for the pathophysiology of dystro-
phin-deficient muscle in which nNOS deficiency and my-
eloid cells contribute significantly to the progression of the
disease. In this model, initial muscle injury is a direct conse-
quence of mechanical damage resulting from the absence of
the membrane-stabilizing effects of dystrophin. However,
muscle inflammation occurs as a secondary consequence of
the mechanical injury, and inflammation may be increased
by the reduction of NO-mediated inhibition of myeloid cell
diapedesis. Activated myeloid cells, especially macrophages,
then release cytolytic molecules from which healthy muscle
can be protected by NO, but from which the cytoprotective
effects of dystrophin-deficient muscle are diminished. This
model suggests that further examination of the use of antiin-
flammatory agents to treat dystrophinopathies could yield
productive, new therapeutic approaches.
Materials and methods
Measurement of macrophage concentration
Mdx mice were killed at 2 wk, 4 wk, or 3 mo of age to represent prene-
crotic, peak necrotic, and regenerative stages of the mdx pathology. Mus-
cles were frozen, sectioned, and immunolabeled for macrophages (anti-
F4/80) or MHC-II (PharMingen). The concentrations of F4/80  cells and
MHC-II  cells were determined by histomorphometry (Spencer et al.,
2001).
Cytotoxicity assays
Muscles from 4-wk-old mdx mice were minced into 2.5 mg/ml collage-
nase (Sigma-Aldrich) in DME and incubated at 37 C for 40 min. The tissue
was transferred to 0.1% trypsin for 30 min, centrifuged, and the cells were
resuspended in 10% FBS in DME. Digested tissue was filtered though a 70-
 m filter and centrifuged. The cells were resuspended in HBSS, overlaid
on Histopaque 1077 (Sigma-Aldrich), and then centrifuged at 400 g for 45
min at 4 C. Macrophages were collected at the HBSS–Histopaque inter-
face. Some cells were then adhered to slides by centrifugation with a
Cytospin (Shandon), and stained with anti-F4/80 to confirm that they were
macrophages. The remaining cells were used for cytotoxicity assays.
C2C12 cells that were used for cytotoxicity assays were plated in 96-
well plates in 10% FBS in DME until confluent, and then placed in serum-
free media overnight to promote fusion. The cells were returned to 10%
FBS for 2 d, and then subjected to serum withdrawal overnight to further
promote fusion. They were then returned to complete media for  4 d be-
fore use in cytotoxicity assays.
Myotubes were incubated in HBSS containing 
51Cr and 0.25% FBS for
2 h and washed in HBSS before use in cytotoxicity assays. Myotubes were
cocultured with macrophages in HBSS containing 0.25% FBS, 400  M ar-
ginine, and 0.6  M PMA for 16 h, after which the media was assayed for
51Cr release by scintillation counting. Macrophages were added at concen-
trations that occur in 4 wk mdx soleus muscles, as determined above. Cy-
totoxicity was expressed as a percentage of total lysis by setting 0% as 
51Cr
released spontaneously by myotubes incubated identically, except without
macrophages. 100% cytotoxicity was set at the 
51Cr release into the media
by myotubes incubated with 0.1% Triton X-100 in HBSS.
Macrophage depletions from mdx mice
Circulating macrophage populations were depleted from mdx mice by re-
peated intraperitoneal injections of anti-F4/80. Antibody from F4/80 hy-
bridoma culture supernatant was isolated by ammonium sulfate precipita-
tion. Precipitated IgG was then resuspended in sterile PBS, and IgG
concentration determined by ELISA assay. Mice undergoing macrophage
depletion received 65  g IgG by intraperitoneal injection in five daily in-
jections per week, beginning at 1 wk of age and continuing to 4 wk of age.
Control animals received injections of the same volume of PBS on the
same schedule. For some animals, serum was assayed for macrophage
concentration in cytospin preparations. Macrophage-depleted animals
showed at least a 90% reduction in circulating macrophage concentra-
tions. Soleus muscles were removed from 4-wk-old animals and used to
assess the presence of membrane lesions or muscle fiber regeneration, as
described below.
Production of NOS Tg mice
Rat brain nNOS in pCMV5 (provided by Dr. James T. Stull, University of
Texas, Southwestern, Dallas, TX) was cloned downstream of the 2.2-kb
human skeletal actin promoter and the vp1 intron (provided by Dr. Jeffrey
Chamberlain, University of Washington, Seattle, WA). The NOS cDNA
was followed by the SV-40 large T poly-A site. The ClaI-DraI–digested
DNA was injected to the pronucleus of F2 hybrid zygotes of C57 Bl6 C3H
parents. Positive transgenic mice were identified by Southern and PCR
analysis for human skeletal actin promoter. Overexpression of the trans-
gene was confirmed by Northern and Western blotting and by gene array
analysis.
Production of NOS Tg/mdx mice
NOS Tg males and mdx females were paired to produce females that were
heterozygous for the dystrophin mutation and males that were hemizygous
for dystrophin deficiency. Thus, all male offspring were dystrophic. Dystro-
phin null mutation was confirmed by ARMS PCR (Amalfitano and Cham-
berlain, 1996). Male offspring that expressed the transgene were identified
by isolating genomic DNA from tail tissue that was digested with protein-
ase K at 55 C overnight. F1 males that did not express the transgene were
used as dystrophic controls.
Inhibition of NOS in vivo
We assessed whether the effects of the presence of the NOS transgene on
mdx muscle pathology were attributable to normalized NO production by
administering NOS inhibitor to NOS Tg/mdx mice. NOS Tg/mdx mice
were supplied with 0.5 mg/ml of N-nitro-L-arginine methyl ester (L-NAME)
in their drinking water from 3 to 4 wk of age. Muscles and sera were col-
lected from the mice at 4 wk of age for analysis of muscle fiber damage,
muscle inflammation, and muscle fiber regeneration, as described below.
Assay of NO release
NO release by unstimulated soleus muscles was measured as described
previously (Tidball et al., 1998).
Assessment of muscle membrane damage
The occurrence of muscle membrane lesions was assessed by testing for
the presence of an extracellular marker dye in the cytoplasm of muscle fi-
bers. Soleus muscles were held at rest length and incubated in 0.2% pro-
cion red in Kreb’s Ringer solution for 1 h and then washed, frozen, cross-
sectioned, and viewed by fluorescent microscopy to identify injured fibers.
Muscle injury was also tested by measuring the concentration of muscle
CK in serum collected by cardiac puncture. CK assays were performed as
described by the manufacturer of the assay kit (Sigma-Aldrich).
Measurement of muscle fiber size variability
Variability of muscle fiber cross-sectional area was evaluated because high
variability of fiber size is a pathological feature of the mdx phenotype
(Bulfield et al., 1984). Fiber cross-sectional area was measured for every fi-
ber in each section using a digitized imaging system (Bioquant). Variability130 The Journal of Cell Biology | Volume 155, Number 1, 2001
in cross-sectional areas between samples was expressed as the mean of the
standard deviations for each population.
Assessment of muscle fiber regeneration
Previous observations have indicated that NO may affect muscle differenti-
ation and regeneration (Lee et al., 1994; Anderson, 2000). We examined
the effect of the NOS transgene on muscle fiber regeneration by determin-
ing the proportion of soleus muscle fibers that were central-nucleated.
Muscle fibers that have experienced injury, repair, and regeneration con-
tain centrally located myonuclei which provide a persistent morphological
indicator of fibers that have experienced damage (Carnwath and Shotton,
1987). The percentage of the total muscle fibers containing central nuclei
that were present in complete cross-sections of entire soleus muscles was
determined microscopically in 4-wk-old and 3-mo-old NOS Tg/mdx and
control mice.
Measurements of muscle vascularity
NO has been shown previously to affect vascularization of tissues (Ziche et
al., 1994; Montrucchio et al., 1997), which could feasibly affect the time
course or severity of the dystrophic pathology. We measured the capillary
density in soleus muscles of 4-wk-old NOS Tg/mdx mice and in their litter-
mates that did not express the transgene using techniques described previ-
ously (Carry et al., 1986). Because measurements of capillary density indi-
cates the number of capillaries, but does not reflect possible differences in
the size of blood vessels, we also measured the percent volume of the
muscles that were comprised of vascular structures. Vascular percent vol-
ume was measured in frozen cross-sections of entire soleus muscles that
were immunolabeled with rat anti–mouse CD31 (PharMingen). CD31 is
expressed constitutively by vascular endothelial cells, so that vascular
structures could be identified unambiguously by anti-CD31 binding. The
luminal area of all vascular structures in each muscle cross-section was
measured microscopically (Bioquant) and the total cross-sectional area of
each section was determined so that vascular percent volume for each
muscle could be calculated.
Gene array analysis
All hindlimb muscles from three NOS Tg mice and three non-Tg litter-
mates were collected and pooled into NOS Tg and control samples. RNA
was isolated as described previously (Chomczynski and Sacchi, 1987). To-
tal RNA was reverse transcribed using a SuperScript system (GIBCO BRL)
with an oligo-dT primer. The cDNA was then used for in vitro transcription
to generate biotinylated cRNA using an ENZO bioarray RNA transcript la-
beling kit (Affymetrix). 15  g of cRNA from each sample was subjected to
random cleavage, after which cRNA samples were hybridized for 16 h at
45 C to an Affymetrix microarray (EukGE-WS2 high density array; murine
U74A gene chip). The microarray was washed with buffer before reacting
biotinylated bound cRNA with streptavidin-conjugated phycoerythrin. The
fluorescent signal corresponding to cRNA bound to each known cDNA in
the microarray was measured using a gene array scanner.
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